Real-World Studies
Baseline Gustave Roussy immune score linked to survival in ES-SCLC cohort
Sánchez-García et alCancer management and research
In a retrospective multi-center study conducted across three Spanish hospitals, researchers evaluated the prognostic value of the baseline Gustave Roussy Immune Score (GRIm) in 51 adult patients with stage IV extensive-stage small-cell lung cancer (ES-SCLC) receiving first-line platinum-etoposide plus a PD-L1 inhibitor between and . The study cohort had a mean age of 64.2 years, 72.5% were male, and 82.3% had an ECOG performance status of 0–1. High-risk GRIm was defined as meeting at least two of three criteria: serum albumin <35 g/L, lactate dehydrogenase above the upper limit of normal, and neutrophil-to-lymphocyte ratio >6.
Across the overall cohort, the objective response rate was 70.6%, with a median overall survival (OS) of 11.9 months and median progression-free survival (PFS) of 5.7 months over follow-up, during which 43 deaths and 50 PFS events occurred. Patients with low-risk baseline GRIm demonstrated a median OS of 14.2 months compared with 5.4 months for those with high-risk GRIm. Baseline Cox proportional hazards modeling adjusting for PLR >180 and ECOG PS ≥2 identified high-risk GRIm as an independent predictor of shorter OS (hazard ratio [HR] 5.59) and PFS (HR 3.50). Additionally, PLR >180 was independently associated with worse OS (HR 2.37). In a 3-month OS landmark analysis (n=47), maintenance chemoimmunotherapy exposure remained associated with prolonged survival (HR 0.21), although residual selection bias cannot be ruled out. The authors concluded that baseline GRIm is a consistent candidate prognostic marker in ES-SCLC, but prospective validation is necessary before applying it to treatment decision-making.
Key Takeaways
- High-risk baseline Gustave Roussy Immune Score (GRIm) was independently associated with significantly worse overall survival (HR 5.59) and progression-free survival (HR 3.50) in patients with extensive-stage small-cell lung cancer receiving first-line chemoimmunotherapy.
- Patients with low-risk GRIm achieved a median overall survival of 14.2 months compared with 5.4 months for those categorized as high-risk GRIm.
- A baseline platelet-to-lymphocyte ratio greater than 180 independently predicted worse overall survival (HR 2.37), whereas exposure to maintenance therapy at a 3-month landmark analysis correlated with improved overall survival (HR 0.21).
Read the original sourceCancer management and research
